[IE-01] Molecular aspects of neurodegenerative disorders

[IE-01-1] Multiple system atrophy: pathophysiology, diagnosis and management

Wassilios Meissner^1,2,3 (1.Université de Bordeaux, Institut des Maladies Neurodégénératives, France, 2.Service de Neurologie, CHU Bordeaux, France, 3.Dept. Medicine, University of Otago, and New Zealand Brain Research Institute, New Zealand)

Prof. Meissner is director of the Parkinson’s disease (PD) Expert Centre Bordeaux and co-chair of the French Reference Centre for multiple system atrophy (MSA). He received his medical degree in 1997 from Humboldt University Berlin (Germany) and his Board Certification in Neurology in 2005 after completing his residency at the Charité University Hospital in Berlin and the University Hospital Bordeaux. In 2005, he was awarded a PhD in Neuroscience at the University Bordeaux. He was appointed Professor of Neurology at the University Bordeaux in 2012. Prof. Meissner is the current chair of the International Education Committee of the International Parkinson and Movement Disorders Society (MDS). His research interests focus on biological and clinical markers of disease progression in PD and MSA, as well as the development of new preclinical models and treatments for these disorders in a translational approach. Within his current research activities, Prof. Meissner chairs the working group of the MDS-sponsored MSA Study Group dedicated to the development of fluid biomarkers, has recently completed a phase 1 study in MSA with two innovative vaccines directed against alpha-synuclein (http://sympath-project.eu) and coordinates the European ARTEMIS consortium that evaluates the efficacy of strategies targeting alpha-synuclein in preclinical models of MSA (http://www.erare.eu/financed-projects/artemis).